Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) spanning five years because of Washington's request for sensitive information.
This rejection was revealed after a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government representative later explained that the US was requesting biological samples for research and commercial gain but was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate task of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had provided over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for continued talks to secure a agreement agreeable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Background
This rejection follows a comparable situation in Kenya, where a court halted a related health funding agreement following legal challenges were raised about the safety of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to boost openness and accountability.
As per statements, Sixteen nations in Africa have to date signed similar agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, with no equivalent promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research with no certainty that the resulting innovations would be available to our citizens should a new disease outbreak emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining frameworks previously set up via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system created to deal with potential global health emergencies.
"This system is designed to ensure that when a country contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We are open to continued discussions with our US partners on how future co-operation could be designed in a way that respects the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body said it understood the official position, but suggested that negotiations should continue given that a large portion of the country's Aids initiatives were funded by international support.
"In cases where specific concerns arise, including those involving information security or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," it commented.
The halted deal highlights the complex tensions between accepting much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.